AMSTERDAM, NEW YORK and IRVINE, Calif., Nov. 29, 2012 /PRNewswire/ -- Saint Mary's Healthcare, the first hospital in New York State to achieve the "Pathway to Excellence" Designation from the American Nurses Credentialing Center, and Masimo (NASDAQ: MASI) today jointly announce that Saint Mary's has standardized to Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, the standard-of-care at leading hospitals worldwide.
Standardizing to Masimo SET® allows clinicians to accurately monitor blood oxygen saturation in challenging conditions establishing the technology as an industry-leading pulse oximetry that substantially contributes to improved patient outcomes.
"The one thing I really appreciate about Masimo's technology is that we've been able to get dependable, reliable readings on neonates," said Rob Noel, Senior Respiratory Therapist at Saint Mary's Healthcare. "We're getting more readings than we were before, especially when movement is involved. When we put this technology on newborns, we know we're getting the right information."
In addition to Masimo SET®, which virtually eliminates false alarms1 and increases a clinician's ability to detect life-threatening events,2 Saint Mary's will benefit from breakthrough rainbow® technology that allows clinicians to measure multiple blood constituents, fluid responsiveness, respiration rate, and other physiological parameters noninvasively and continuously. Parameters at Saint Mary's include total hemoglobin (SpHb®), and carboxyhemoglobin (SpCO®), as well as the Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR).
Saint Mary's will deploy SpHb in its emergency department. Masimo SpHb enables clinicians to measure hemoglobin and trending noninvasively and continuously.3 A recent study also noted that, "Because SpHb measurement is noninvasive, it has the potential to confer the additional benefits of patient comfort, decreased complexity, and increased safety for health care providers who are not exposed to risks of needle-stick injury and blood-spill contaminations."4 Likewise, SpCO allows clinicians to noninvasively and quickly detect elevated levels of carbon monoxide in the blood facilitating earlier diagnosis and treatment.5
According to Peter Holtermann, Director of Medical Imaging at Saint Mary's, "The true benefit of the standardized equipment is to the patient. The accuracy of the testing and its less invasive nature enable patients to receive care that is less painful and more timely."
"We are happy to have this partnership with Saint Mary's, which like other great healthcare organizations is demonstrating its commitment to patient safety and care by taking advantage of our breakthrough patient monitoring technologies such as SpHb a continuous noninvasive way to measure total hemoglobin, and our measure-through motion and low perfusion pulse oximetry technology, which has been proven to improve care and reduce costs," said Masimo founder and CEO Joe Kiani. "Together, we look forward to helping Saint Mary's meet and exceed its patient-care needs."
1 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
3 Frasca D., Dahyot-Fizelier C., Catherine K., Levrat Q., Debaene B., Mimoz O. "Accuracy of a Continuous Noninvasive Hemoglobin Monitor in Intensive Care Unit Patients."Crit Care Med. 2011 Oct;39(10):2277-82. Available online here.
4 Raikhel M. "Accuracy of Noninvasive and Invasive Point-of-Care Total Blood Hemoglobin Measurement in an Outpatient Setting" Postgraduate Medicine, Volume 124, Issue 4, July 2012, ISSN 0032-5481, e-ISSN 1941-9260.
5 Hampson N. "Noninvasive pulse CO-oximetry expedites evaluation and management of patients with carbon monoxide poisoning." The American Journal of Emergency Medicine 2012 (10.1016/j.ajem.2012.03.026) Available online here
About Saint Mary's Healthcare
St. Mary's Healthcare is a continuum of health care services offering a comprehensive network of high quality, local, compassionate care. Services include but are not limited to 120 acute care beds, 10 primary and specialty care centers in Fulton and Montgomery counties, more than 30 behavioral health services in Fulton, Montgomery and Hamilton counties, a 10 bed Acute Inpatient Rehabilitation Unit, a 10 bed Transitional Care Unit, and a 160-bed nursing home. St. Mary's received 5-star ratings from HealthGrades for four consecutive years and in 2011 became the first hospital in New York State to achieve the "Pathway to Excellence" Designation. Our 1600+ associates embrace the mission of providing every individual with an exceptional patient experience. Founded by the Sisters of St. Joseph of Carondelet in 1903, and as a member of Ascension Health since 2002, St. Mary's is dedicated to improving the health of the community with special attention to the poor and underserved. Please visit www.smha.org.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient carehelping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb) and SpCO contribute to positive clinical outcomes and patient safety under all circumstances; risks related to our belief that Masimo noninvasive medical breakthroughs provide solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.